Evidence map›Paper›PMID 35406383›Full record

ArticleCancers2022

Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model.

Tejaswi Worlikar, Man Zhang, Anutosh Ganguly, Timothy L Hall, Jiaqi Shi, Lili Zhao, Fred T Lee, Mishal Mendiratta-Lala, Clifford S Cho, Zhen Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tejaswi WorlikarDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0001-6828-022X
Man ZhangDepartment of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
Anutosh GangulyDepartment of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Timothy L HallDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Jiaqi ShiDepartment of Pathology & Clinical Labs, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-4893-1587
Lili ZhaoDepartment of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.
Fred T LeeDepartment of Radiology, University of Wisconsin, Madison, WI 53705, USA.
Mishal Mendiratta-LalaDepartment of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
Clifford S ChoDepartment of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Zhen XuDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
University of Michigan · USUniversity of Wisconsin–Madison · US

Funding

Novel, Noninvasive, Rapid Tumor Ablation Technology using HistotripsyR01CA211217 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI XU, ZHEN · 2018 to 2022
$2.7M
Linking epigenetic regulation and TGF-β signaling in pancreatic cancerK08CA234222 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHI, JIAQI · 2018 to 2021
$744k
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapyI01BX001619 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI CHO, CLIFFORD · 2014 to 2022
–
BLRD VA I01 BX001619NCI NIH HHS K08 CA234222NCI NIH HHS R01 CA211217NIH HHS R01 CA211217, K08 CA234222
6 · The paper itself

Abstract

Histotripsy has been used for tumor ablation, through controlled, non-invasive acoustic cavitation. This is the first study to evaluate the impact of partial histotripsy ablation on immune infiltration, survival outcomes, and metastasis development, in an in vivo orthotopic, immunocompetent rat HCC model (McA-RH7777). At 7−9 days post-tumor inoculation, the tumor grew to 5−10 mm, and ~50−75% tumor volume was treated by ultrasound-guided histotripsy, by delivering 1−2 cycle histotripsy pulses at 100 Hz PRF (focal peak negative pressure P− >30 MPa), using a custom 1 MHz transducer. Complete local tumor regression was observed on MRI in 9/11 histotripsy-treated rats, with no local recurrence or metastasis up to the 12-week study end point, and only a <1 mm residual scar tissue observed on histology. In comparison, 100% of untreated control animals demonstrated local tumor progression, developed intrahepatic metastases, and were euthanized at 1−3 weeks. Survival outcomes in histotripsy-treated animals were significantly improved compared to controls (p-value < 0.0001). There was evidence of potentially epithelial-to-mesenchymal transition (EMT) in control tumor and tissue healing in histotripsy-treated tumors. At 2- and 7-days post-histotripsy, increased immune infiltration of CD11b+, CD8+ and NK cells was observed, as compared to controls, which may have contributed to the eventual regression of the untargeted tumor region in histotripsy-treated tumors.

Indexed as

hepatocellular carcinomahistotripsyimmunomodulationmetastasestumor ablation

Identifiers

PMID35406383
PMCPMC8996987
OpenAlexW4220653572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.